Indoco Remedies Ltd. has announced that the company has received a certificate for EU Good Manufacturing Practices (GMP) compliance from the European Health Authorities for its sterile drug product manufacturing facility located in South Goa – Goa Plant II.

The EU GMP certification issued by the European Health Authorities confirms that the site complies with the Good Manufacturing Practice requirements, the company said in a statement.

Commenting on the development, Aditi Panandikar, Managing Director, Indoco Remedies Ltd., said, “This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies. We remain fully committed to adhering to cGMP standards and consistently delivering quality products to customers and patients worldwide.”

Indoco is a fully integrated, research-oriented pharmaceutical company with a strong global presence. The company has 11 manufacturing facilities, 7 for FDFs and 4 for APIs, supported by a state-of-the-art R&D centre and a CRO facility. The facilities have been approved by most of the regulatory authorities including USFDA and UK-MHRA. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets.